Short Interest in Tema Oncology ETF (NASDAQ:CANC) Declines By 47.3%

Posted by Donna Armstrong on Aug 30th, 2026

Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the target of a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 10,698 shares, a decline of 47.3% from the July 30th total of 20,291 shares. Based on an average daily trading volume, of 17,651 shares, the short-interest ratio is currently 0.6 days. Currently, 0.2% of the shares of the company are sold short.

Institutional Investors Weigh In On Tema Oncology ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Roxbury Financial LLC bought a new position in Tema Oncology ETF during the first quarter worth $34,000. LPL Financial LLC acquired a new position in Tema Oncology ETF in the fourth quarter valued at approximately $278,000. Jane Street Group LLC purchased a new position in Tema Oncology ETF in the first quarter valued at about $213,000. Flow Traders U.S. LLC purchased a new stake in Tema Oncology ETF during the third quarter valued at about $630,000. Finally, Thrivent Financial for Lutherans lifted its stake in Tema Oncology ETF by 891.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock worth $50,747,000 after acquiring an additional 1,314,177 shares during the period.

Tema Oncology ETF Trading Down 2.8%

Shares of NASDAQ CANC traded down $1.27 during midday trading on Friday, reaching $43.52. The company’s stock had a trading volume of 22,433 shares, compared to its average volume of 31,679. The company has a market cap of $207.59 million, a price-to-earnings ratio of 20.39 and a beta of 0.68. The company has a 50 day moving average price of $41.87 and a 200 day moving average price of $38.84. Tema Oncology ETF has a one year low of $26.52 and a one year high of $47.00.

Tema Oncology ETF Company Profile

(Get Free Report)

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.